ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting

    Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review

    Rongqiang Zhang1, Puwei Yuan2, Jia Li3, Bo Dong1, Wulin Kang3, Stephanie Hyon4, Raveendhara R. Bannuru5, William F. Harvey4 and Chenchen Wang4, 1Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, 2Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, 3Shaanxi University of Chinese Medicine, Xianyang, China, 4Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, 5Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA

    Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
  • Abstract Number: 2462 • 2017 ACR/ARHP Annual Meeting

    Tapering TNF Inhibitors in Rheumatoid Arthritis: A Retrospective Study

    Ayse Hacioglu1, Gulen Hatemi2, Sinem Nihal Esatoglu2, Yesim Ozguler2, Serdal Ugurlu1, Emire Seyahi2, Melike Melikoglu2, Izzet Fresko2, Huri Ozdogan2, Sebahattin Yurdakul2 and Vedat Hamuryudan2, 1Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Current guidelines on RA treatment recommend tapering of biologic DMARDs for patients in persistent remission. Methods: In this retrospective study we used the hospital…
  • Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting

    Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab

    Lorie A. Ellis1, Ismail Simsek2, Lin Xie3, Adesuwa Ogbomo3, Dennis Parenti4, Kavitha Goyal4 and Yusuf Yazici5, 1Janssen HECOR Immunology, Horsham, PA, 2Guven Hospital, Ankara, Turkey, 3STATinMED Research Inc., Ann Arbor, MI, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5New York University School of Medicine, New York, NY

    Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
  • Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting

    Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal

    Liam O'Neil1, Victor Spicer2, Carol A Hitchon2, Juergen Rech3, Axel J. Hueber4, John Wilkins2, Hani El-Gabalawy1 and Georg Schett3, 1Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 4Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…
  • Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?

    Adeeba Al-Herz1, Aqeel Ghanem2, Khulood Saleh3, Adel Al-Awadhi4, Waleed Al-Kandari3, Eman Hasan5, Mohammad Hussain5, Ibrahim Nahar2, Fatemah Abutiban6, Ahmad Alenizi6, Yaser Ali2, Ali Aldei1, Hebah Alhajeri2, Sawsan Hayat2, Ahmad Khadrawy3, Ammad Fazal3, Khaled Mokaddem1, Agaz Zaman2, Ghada Mazloum2, Youssef Bartella1, Sally Hamed1, Ramia Alsouk6 and Ahmed Al-Saber7, 1Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, 2Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 3Rheumatology, Farwania Hospital, Farwania, Kuwait, 4Faculty of Medicine, Kuwait, Kuwait, 5Al-Amiri Hospital, Kuwait city, Kuwait, 6Rheumatology, Jahra Hospital, Jahra, Kuwait, 7Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait

    Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
  • Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting

    Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis Patients Who Had Inadequate Response to Biologic Dmards

    Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan

    Background/Purpose:  Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…
  • Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting

    Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology

    Adam Paul Croft1, Joana Campos2, Loriane Savary2, Emma Bishop2, Jason Turner1, Guillaume Desanti2, Francesca Barone3, Andrew Filer3 and Chris Buckley2, 1Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…
  • Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting

    Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis

    Joseph Tkacz1, Edward Lee2, Robert Low2, Jeffrey Stark2, Mohamed Yassine2 and Brenna Brady1, 1Health Analytics LLC, Columbia, MD, 2UCB Pharma, Smyrna, GA

    Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
  • Abstract Number: 1079 • 2017 ACR/ARHP Annual Meeting

    Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis

    Rodrigo Garcia Salinas1, Sebastian Magri2 and Facundo Salvatori3, 1Section of Rheumatology, Hospital Italiano de La Plata, Buenos Aires, Argentina, La Plata, Argentina, 2Section of Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina, 3Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina

    Background/Purpose: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has…
  • Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting

    Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration

    Richard Bell1, Emily Wu1,2, Homaira Rahimi3 and Edward Schwarz1,4,5, 1Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 2Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 3Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, 4University of Rochester, Rochester, NY, 5Univ of Rochester Med Ctr, University of Rochester School of Medicine and Dentistry, Rochester, NY

    Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…
  • Abstract Number: 1349 • 2017 ACR/ARHP Annual Meeting

    Treat to Target: What’s the Target?

    Philip Dunn1, Jonida Cote1, Eric Newman2 and Lester Kirchner1, 1Geisinger Medical Center, Danville, PA, 2Department of Rheumatology, Geisinger Medical Center, Danville, PA

    Background/Purpose: The 2015 ACR RA treatment guidelines focus on measuring disease activity and provide a guideline driven treat to target strategy. We hope to understand…
  • Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting

    The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate

    Josef S. Smolen1, Nael Mostafa2, Xin Huang2, Peter Noertersheuser3, Ben Klünder3, Kun Chen2, Jasmina Kalabic3, Iain Sainsbury2, Ruud Oerlemans4, Stefan Florentinus4 and Gerd R. Burmester5, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2AbbVie Inc., North Chicago, IL, 3AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 4AbbVie, Nederland, Hoofddorp, Netherlands, 5Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany

    Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…
  • Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting

    Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry

    Philip J Mease1, Neil Accortt2, Mei Liu3, Sabrina Rebello3, Mahdi Gharaibeh2 and David Collier2, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Amgen Inc., Thousand Oaks, CA, 3Corrona, LLC, Southborough, MA

    Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
  • Abstract Number: 1703 • 2017 ACR/ARHP Annual Meeting

    A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One Tnfα Inhibitor

    Suzanne Kafaja1, Donna Skerrett2, Silviu Itescu3 and Daniel E. Furst4, 1Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, 2Mesoblast Inc., New York, NY, 3mesoblast Inc., New York, NY, 4David Geffen School of Medicine at UCLA, Los Angeles, CA

    Background/Purpose: Allogeneic STRO-3 immunoselected mesenchymal precursor cells (MPCs) derived from bone marrow of healthy donors are a potent, homogeneous cell population which can be activated…
  • Abstract Number: 353 • 2017 ACR/ARHP Annual Meeting

    Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey

    Cheryl L. Koehn1, Kelly Lendvoy1, Yue Ma2, Linda Li3, Alison Hoens4, Marion Souveton5 and John M. Esdaile4, 1Arthritis Consumer Experts, Vancouver, BC, Canada, 2Simon Fraser University, Burnaby, BC, Canada, 3Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, 4Arthritis Research Canada, Richmond, BC, Canada, 5F. Hoffmann-La Roche Ltd, Basel, Switzerland

    Background/Purpose: Despite the global prevalence of rheumatoid arthritis (RA), there is no single model of care (MoC) and little is known about the RA patient…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology